The Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device (DOSED) Study is a study for individuals with spinal cord injury (SCI) to evaluate the safety of a new device to deliver cells (LCTOPC1) directly into the spinal cord.  This cell type facilitates electrical signal conduction of nerves.

The study will enroll 6-10 participants with either subacute or chronic SCI across multiple clinical trial sites in the Unites States.

SCI is a serious condition that affects the ability to move, feel, and control some body functions. SCI can have a major impact on the quality of life of the affected person and their family. Currently, there is no cure for SCI.

More detailed information may be found at clinicaltrials.gov.